AlzeCure Pharma has reported that the last patient's last visit has taken place in its ongoing Phase Ib trial of ACD856, the lead compound in the company's NeuroRestore platform. The Swedish biotech is developing the drug as an oral treatment for Alzheimer's disease, with depression named as a possible additional indication.
The study was designed to test safety and tolerability when ACD856 is given repeatedly at higher doses than in earlier trials, and to measure how much of the substance ends up circulating in the body. According to the company, earlier preclinical and clinical work pointed to a strong safety and tolerability profile, which is what opened the door to pushing the dose upward. In drug development terms, that matters: a wide therapeutic window gives researchers room to find a dose high enough to do something useful without running into unacceptable side effects.
ACD856 belongs to a class AlzeCure calls Trk-PAM substances, which amplify signalling through BDNF and NGF - growth factor pathways tied to how neurons communicate. The company has previously reported data showing the compound crosses the blood-brain barrier at relevant concentrations and switches on pathways involved in both cognition and depression. In animal models, NeuroRestore compounds have been described as strengthening communication between neurons and improving learning and memory, along with neuroprotective, anti-inflammatory and disease-modifying effects.
This is an early stage of testing. Phase Ib studies are about safety, tolerability and drug levels in the body, not about whether a treatment slows or improves Alzheimer's symptoms in patients. The results from this trial will determine whether and at what dose ACD856 moves into larger efficacy studies.